{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"0.0","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"CYCLE 1 DAY -2, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"771.0","value":"449.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"CYCLE 1 DAY -2, 30 MINUTES"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"912.0","value":"453.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY -2, 1 HOUR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.2","upperLimit":"582.0","value":"294.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY -2, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.6","upperLimit":"271.0","value":"147.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY -2, 4 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.5","upperLimit":"885.0","value":"93.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.6","upperLimit":"441.0","value":"110.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"CYCLE 1 DAY 4, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.3","upperLimit":"306.0","value":"133.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"title":"CYCLE 1 DAY 8, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"751.0","value":"106.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, PRE-DOSE"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"1010.0","value":"415.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 30 MINUTES"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"1150.0","value":"429.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 1 HOUR"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.3","upperLimit":"864.0","value":"433.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 2 HOURS"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"91.1","upperLimit":"425.0","value":"217.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"CYCLE 2 DAY 1, 4 HOURS"}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis of Nirogacestat when administered orally in combination with belantamab mafodotin.","dispersionType":"Full Range","groups":[{"description":"Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 0.5 mg/kg belantamab mafodotin intravenous (IV) infusion as powder for solution once every 4 weeks (Q4W) infused over 30- 60 minutes on day 1 of each 28-day cycle in combination with 100 mg Nirogacestat administered orally twice a day (BID) up to Day 28. Along with 4 mg Pomalidomide orally per day (QD) on Days 1-21 of each 28-day cycle and Dexamethasone 40mg (20 mg for participants \\>75 years old or BMI \\<18.5 kg/m\\^2) administered orally on days 1, 8, 15 and 22 of each 28-day cycle.","id":"OG000","title":"0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Pomalidomide + Dexamethasone"}],"paramType":"MEDIAN","populationDescription":"PK population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Predose, 30 mins, 1 hour, 2 hours, and 4 hours post dose on Cycle 1 Day -2; Predose on Cycle 1 Day 1, 4, 8; Predose, 30 mins, 1 hour, 2 hours, and 4 hours post dose on Cycle 2 Day 1","title":"DE Phase: Nirogacestat Concentration When Administered in Combination With Belantamab Mafodotin","type":"SECONDARY","unitOfMeasure":"ng/mL"}